If you'll remember, back when Pfizer launched Exubera, the inhaled insulin, with a lot of press hype, I was interviewed by Business Week as a "typical patient" and I quoted (very vaguely) about why I thought Exubera was a bad idea for people with diabetes.It looks like I was onto something.Today the AP is carrying a story about how endocrinologists have proved resistant to Pfizer's push to
